NDC 62856-215

LEQEMBI

Lecanemab

LEQEMBI is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Eisai Inc.. The primary component is Lecanemab.

Product ID62856-215_aff5d037-645b-4220-95e5-8ac9775f92a0
NDC62856-215
Product TypeHuman Prescription Drug
Proprietary NameLEQEMBI
Generic NameLecanemab
Dosage FormInjection, Solution
Route of AdministrationINTRAVENOUS
Marketing Start Date2023-01-06
Marketing CategoryBLA /
Application NumberBLA761269
Labeler NameEisai Inc.
Substance NameLECANEMAB
Active Ingredient Strength100 mg/mL
NDC Exclude FlagN
Listing Certified Through2024-12-31

Packaging

NDC 62856-215-01

1 VIAL, SINGLE-DOSE in 1 CARTON (62856-215-01) > 5 mL in 1 VIAL, SINGLE-DOSE
Marketing Start Date2023-01-06
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "LEQEMBI" or generic name "Lecanemab"

NDCBrand NameGeneric Name
62856-212LEQEMBIlecanemab
62856-215LEQEMBIlecanemab

Trademark Results [LEQEMBI]

Mark Image

Registration | Serial
Company
Trademark
Application Date
LEQEMBI
LEQEMBI
97151804 not registered Live/Pending
Eisai R&D Management Co., Ltd.
2021-12-01

© 2023 FDA.report
This site is not affiliated with or endorsed by the FDA.